Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · April 11, 2022

Nivolumab +/− Ifosfamide, Carboplatin, and Etoposide for R/R Hodgkin Lymphoma

Blood

 

 Save  Recommend
 Share

Additional Info

Blood
Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE)
Blood 2022 Mar 22;[EPub Ahead of Print], MG Mei, HJ Lee, J Palmer, RW Chen, NC Tsai, L Chen, K McBride, DL Smith, I Melgar, JY Song, KC Bonjoc, S Armenian, M Nwangwu, P Lee, J Zain, L Nikolaenko, L Popplewell, A Nademanee, AA Chaudhry, ST Rosen, LW Kwak, SJ Forman, AF Herrera

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated